文献速递肺结节与肺癌

HOMER模型:辅助肺癌纵隔分期以筛选放疗候选者

A Prediction Model to Help with Oncologic Mediastinal Evaluation for Radiation: HOMER.
PubMed 文献 · Am J Respir Crit Care Med · 2020-01-01

本研究基于单中心633例接受支气管内超声分期的NSCLC患者,开发了预测N0、N1、N2|3疾病的模型,并在同中心3年后473例及另外三家医院722例中验证。模型预测N1及以上和N2|3的AUC在开发队列为0.84和0.86,外部验证为0.86和0.88但需校准。该模型有助于在考虑立体定向消融放疗时辅助决策。

要点

  • HOMER模型可估计NSCLC患者N0、N1、N2|3的概率。
  • 模型预测N1及以上和N2|3的AUC在验证队列为0.86和0.88。
  • 外部验证需校准,校准后模型拟合可接受。

核心结论

  • 该预测模型能估计NSCLC患者N0、N1和N2|3疾病的概率。
  • 模型有潜力在立体定向消融放疗为选项时辅助决策。

研究设计与样本

  • 开发队列为单中心连续接受支气管内超声分期的临床影像T1-T3、N0-N3、M0的NSCLC患者633例。
  • 采用多变量有序logistic回归预测N0、N1或N2|3疾病。
  • 时间验证使用同中心3年后连续患者473例。
  • 外部验证使用另外三家医院患者722例。

主要发现

  • 开发队列中,较年轻年龄、中央位置、腺癌和较高PET-CT淋巴结分期与更高概率的晚期淋巴结疾病相关。
  • 开发队列预测N1或更高(vs N0)和N2|3(vs N0或N1)的AUC分别为0.84和0.86。
  • 时间验证队列预测N1或更高和N2|3的AUC分别为0.86和0.88。
  • 外部验证队列预测N1或更高和N2|3的AUC分别为0.86和0.88。
  • 外部验证队列需校准(Hosmer-Lemeshow P<0.001),校准后模型拟合可接受(Hosmer-Lemeshow P=0.094)。

临床怎么用

  • 对于考虑立体定向消融放疗的NSCLC患者,可用HOMER模型估计纵隔淋巴结分期概率以辅助治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: When stereotactic ablative radiotherapy is an option for patients with non-small cell lung cancer (NSCLC), distinguishing between N0, N1, and N2 or N3 (N2|3) disease is important.Objectives: To develop a prediction model for estimating the probability of N0, N1, and N2|3 disease.Methods: Consecutive patients with clinical-radiographic stage T1 to T3, N0 to N3, and M0 NSCLC who underwent endobronchial ultrasound-guided staging from a single center were included. Multivariate ordinal logistic regression analysis was used to predict the presence of N0, N1, or N2|3 disease. Temporal validation used consecutive patients from 3 years later at the same center. External validation used three other hospitals.Measurements and Main Results: In the model development cohort (n = 633), younger age, central location, adenocarcinoma, and higher positron emission tomography-computed tomography nodal stage were associated with a higher probability of having advanced nodal disease. Areas under the receiver operating characteristic curve (AUCs) were 0.84 and 0.86 for predicting N1 or higher (vs. N0) disease and N2|3 (vs. N0 or N1) disease, respectively. Model fit was acceptable (Hosmer-Lemeshow, P = 0.960; Brier score, 0.36). In the temporal validation cohort (n = 473), AUCs were 0.86 and 0.88. Model fit was acceptable (Hosmer-Lemeshow, P = 0.172; Brier score, 0.30). In the external validation cohort (n = 722), AUCs were 0.86 and 0.88 but required calibration (Hosmer-Lemeshow, P < 0.001; Brier score, 0.38). Calibration using the general calibration method resulted in acceptable model fit (Hosmer-Lemeshow, P = 0.094; Brier score, 0.34).Conclusions: This prediction model can estimate the probability of N0, N1, and N2|3 disease in patients with NSCLC. The model has the potential to facilitate decision-making in patients with NSCLC when stereotactic ablative radiotherapy is an option.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Martinez-Zayas G, Almeida FA, Simoff MJ, et al. A Prediction Model to Help with Oncologic Mediastinal Evaluation for Radiation: HOMER. Am J Respir Crit Care Med. 2020. PMID: 31574238. doi:10.1164/rccm.201904-0831OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。